STATUS · OF RECORD · GENERAL INFORMATION
BPC-157 Legal Status, FDA 503A Category, and Compounding Access
Where access stands today, what is under active FDA review for 2026, and how legally compounded peptide access works in general — present-tense facts, cited to the FDA.
Access is under active FDA review and may expand in 2026
The forward-looking fact first: the BPC-157 legal status picture is in motion. Access is under active FDA review, and it may expand in 2026. The peptide is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed — through its FDA entries "BPC-157 (free base)" and "BPC-157 acetate" — as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [3]. The same agenda also lists KPV, TB-500, and MOTs-C [3].
What that is, precisely: a scheduled evaluation and discussion. A PCAC discussion is advisory and is a step in FDA's evaluation, not a final listing decision, not a reclassification, and not a change in current status [1][3]. The committee being scheduled to consider a substance for the bulks list means its evaluation is ongoing — it does not mean an outcome has been reached, and no outcome should be assumed or dated. The momentum is real and citable; the result is not yet written.
What is the FDA 503A status of BPC-157 right now?
As a present-tense fact, FDA placed BPC-157 in 503A "Category 2" — bulk substances that may present significant safety risks — effective with FDA's September 29, 2023 update to the list of nominated bulk drug substances [2]. The FDA cited concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [2]. The category placement applies to the FDA list entries "BPC-157 (free base)" and "BPC-157 acetate" [2].
Two consequences follow directly. First, because it is a Category 2 substance, BPC-157 is not within FDA's enforcement-discretion policy for 503A compounding — the policy that applies to Category 1 substances does not extend to Category 2 [1][2]. Second, BPC-157 is not an FDA-approved drug; FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding, and BPC-157 satisfies neither [1]. If a date must be stated in any summary of this status, cite the FDA page rather than restating September 29, 2023 as independently established [2].
How the 503A and 503B framework works
Under the Federal Food, Drug, and Cosmetic Act, two sections govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection [1].
A compounder may use a bulk drug substance — an active ingredient used as a starting material rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list [1]. Substances not yet on a bulks list are evaluated through a public nomination process with input from the PCAC [1]. FDA's interim policy sorted nominated substances into Category 1 (covered by enforcement discretion while under evaluation) and Category 2 (identified as raising significant safety risks; not covered) [1]. On January 7, 2025, FDA finalized a revised policy under which it no longer places newly nominated substances into these numbered categories, while stating that Category 2 substances are not afforded enforcement discretion even if nominations are updated [1][5].
How legally compounded peptide access works in general
In the United States, a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [1]. The preparation is then made either by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, by an FDA-registered 503B outsourcing facility [1].
Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued [1]. It is a route to a licensed-prescriber consultation, not a separate legal status: telehealth does not expand which substances may be compounded and does not remove the requirement for a legitimate prescriber-patient relationship and a valid prescription [1].
One caveat governs all of this for BPC-157 specifically. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A and 503B bulk-substance rules; ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands [1]. As long as BPC-157 remains in Category 2, it is not eligible for routine 503A compounding [1][2] — so the general compounding access pathway described above does not currently reach BPC-157 by the routine 503A route while that status stands. This page names no pharmacy, clinic, telehealth provider, or vendor, gives no dosing, and describes no way to obtain a restricted substance outside the lawful framework — it is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance.
Is BPC-157 legal?
BPC-157 is not an FDA-approved drug, and FDA placed it in 503A Category 2 — substances that may present significant safety risks — effective September 29, 2023, which means it is not within FDA's enforcement-discretion policy for 503A compounding [1][2]. This is general regulatory information, not legal advice. BPC-157 is also prohibited in sport at all times by the World Anti-Doping Agency under its non-approved-substances category.
Can you get BPC-157 from a compounding pharmacy?
A compounding pharmacy may use a bulk drug substance only if it is eligible under the 503A or 503B rules; while BPC-157 stands in Category 2, it is not eligible for routine 503A compounding [1][2]. Lawful compounded access otherwise runs through a licensed-prescriber evaluation and a valid, patient-specific prescription. This is general information and names no pharmacy, clinic, or provider.
What is the FDA 503A status of BPC-157?
FDA placed BPC-157 (the entries "BPC-157 (free base)" and "BPC-157 acetate") in 503A Category 2 — bulk substances that may present significant safety risks — effective with the September 29, 2023 nominated-substances update, citing immunogenicity and peptide-impurity and characterization concerns [2]. It is therefore not within FDA's enforcement-discretion policy for 503A compounding [1][2]. It is separately scheduled for PCAC discussion on July 23-24, 2026, which is an evaluation step, not a decision [3].